Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

158.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
48 49 Next >
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
From Biogen Inc.
Via GlobeNewswire
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing... 
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors. 
Via The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners. 
Via InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
Better Buy: Biogen vs. Eli Lilly
This battle of biotech giants has a clear winner. 
Via The Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Biogen Appoints Jane Grogan as Head of Research
From Biogen Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
The company is now focusing on its launch in postpartum depression. 
Via Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5% 
Via InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
The pharmaceutical company's growth prospects have taken a big hit. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Shares of Sage Therapeutics Slumped This Week
The company got bad news from the FDA and saw increased losses. 
Via The Motley Fool
Exposures Product Safety
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
The company's rare disease portfolio may soon get an upgrade. 
Via The Motley Fool
With an Acquisition on the Way, Is Biogen Stock a Buy?
Can the biotech finally get back in the good graces of investors? 
Via The Motley Fool
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
Lilly shares surged 15% in one day to a record high. Here's what you should know. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.